<DOC>
	<DOC>NCT00839241</DOC>
	<brief_summary>The primary objective of the study is to compare the immunological status after either autologous blood transfusion as administered by BellovacÂ® ABT or allogenic blood transfusion, with regards to change in Natural Killer (NK) cell frequency in patients undergoing total knee replacement.</brief_summary>
	<brief_title>A Clinical Study to Investigate if Transfusion of Patients Own Shed Blood Improves the Immunological Status in Comparison to Transfusion of Donor Blood ("Bank Blood")</brief_title>
	<detailed_description />
	<criteria>Provision of informed consent Male and female patients aged 18 years and over scheduled for total knee replacement Subjects classified as ASA Physical Status Classification System class P1, P2 or P3 according to the American Society of Anaesthesiology Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site) Preoperatively haemoglobin below normal range as judged by the investigator Previous enrolment or randomisation to treatment in the present study Expected or confirmed participation in another clinical study during the study period Severe noncompliance to protocol as judged by the investigator and/or Astra Tech Current symptoms of haemophilia History of or presence of malignant disease with propensity for systemic spread during the last 5 years Current or expected use of cytotoxic drugs Current untreated anaemia (e.g. sickle cell anaemia) as deemed by investigator Use of predonation Use of recombinant erythropoetin Use of other autologous blood transfusion than that with Bellovac ABT, e.g. washed and centrifuged blood like CellSaver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>